What is the appropriate oral ciprofloxacin (Cipro) dose and treatment duration for an adult with a wound infection? | Rounds What is the appropriate oral ciprofloxacin (Cipro) dose and treatment duration for an adult with a wound infection? | Rounds
Loading...

What is the appropriate oral ciprofloxacin (Cipro) dose and treatment duration for an adult with a wound infection?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: July 14, 2026 · View editorial policy

Oral Ciprofloxacin Dosing for Adult Wound Infections

For most adult bacterial skin and soft-tissue (wound) infections, ciprofloxacin dosing should be based on organism susceptibility, and treatment duration should be 7–14 days. [1]

Medication Selection Algorithm

  • Ciprofloxacin is appropriate for wound infections caused by gram-negative organisms or Pseudomonas aeruginosa when susceptibility is confirmed or strongly suspected. [1]
  • Ciprofloxacin should not be used for routine coverage of typical gram-positive skin flora unless susceptibility is confirmed. [1]

Appropriate Oral Dose

  • 500 mg PO twice daily is recommended for mild to moderate skin and soft-tissue infections. [2]
  • 750 mg PO twice daily is recommended for severe or complicated infections. [2]

Treatment Duration

  • Treatment for most bacterial skin and soft-tissue infections is recommended for 7–14 days. (Class/Level: strong, moderate) [1]

Treatment Response Guidance

  • Ciprofloxacin is administered for the full planned course duration even when early clinical improvement occurs. [1], [2]

Common Pitfalls to Avoid

  • In wound infections with abscess, antibiotics alone are inadequate because drainage is required for source control. (Recommendation for drainage of soft tissue abscess: strong, low) [1]

Practical Duration Reassessment

  • Duration should be reassessed based on clinical improvement and failure to improve within the expected early response window. [1]

Related Questions